<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Xu Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>&lt;i>APOE&lt;/i> -ρ.4 is the strongest genetic risk factor for Alzheimer's disease (AD), and plasma phosphorylated tau217 (P-tau217) is a highly sensitive and specific biomarker for AD pathology. Their combined utility to predict cognitive decline before onset of AD has not been systematically evaluated.&lt;h4>Methods&lt;/h4>Using longitudinal data from multiple cohorts, we evaluated plasma P-tau217 as a predictor of when cognitive impairment occurs in AD. P-tau217 concentrations were analyzed as continuous and binary variables using cohort-specific biomarker positivity thresholds. Association of plasma P-tau217 with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by &lt;i>APOE&lt;/i> genotype. Adjusted survival curves and re</pubmed_abstract><journal>medRxiv : the preprint server for health sciences</journal><pagination>2026.02.06.26345774</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12919147</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predictive Value of Plasma P-tau217 and &amp;lt;i&amp;gt;APOE&amp;lt;/i&amp;gt; Genotype for Preclinical Cognitive Decline in Alzheimer's Disease.</pubmed_title><pmcid>PMC12919147</pmcid><pubmed_authors>Petersen M</pubmed_authors><pubmed_authors>Mejia DR</pubmed_authors><pubmed_authors>Reyes RER</pubmed_authors><pubmed_authors>Wilson R</pubmed_authors><pubmed_authors>Mayeux R</pubmed_authors><pubmed_authors>Gu Y</pubmed_authors><pubmed_authors>O'Bryant S</pubmed_authors><pubmed_authors>Medrano M</pubmed_authors><pubmed_authors>Brickman AM</pubmed_authors><pubmed_authors>Reyes-Dumeyer D</pubmed_authors><pubmed_authors>Johnson S</pubmed_authors><pubmed_authors>Manly JJ</pubmed_authors><pubmed_authors>Engelman CD</pubmed_authors><pubmed_authors>Gunasekaran TI</pubmed_authors><pubmed_authors>Bennett DA</pubmed_authors><pubmed_authors>Sanchez D</pubmed_authors><pubmed_authors>Honig L</pubmed_authors><pubmed_authors>Piriz A</pubmed_authors><pubmed_authors>Lantigua RA</pubmed_authors><pubmed_authors>Asthana S</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Vardarajan BN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predictive Value of Plasma P-tau217 and &amp;lt;i&amp;gt;APOE&amp;lt;/i&amp;gt; Genotype for Preclinical Cognitive Decline in Alzheimer's Disease.</name><description>&lt;h4>Background&lt;/h4>&lt;i>APOE&lt;/i> -ρ.4 is the strongest genetic risk factor for Alzheimer's disease (AD), and plasma phosphorylated tau217 (P-tau217) is a highly sensitive and specific biomarker for AD pathology. Their combined utility to predict cognitive decline before onset of AD has not been systematically evaluated.&lt;h4>Methods&lt;/h4>Using longitudinal data from multiple cohorts, we evaluated plasma P-tau217 as a predictor of when cognitive impairment occurs in AD. P-tau217 concentrations were analyzed as continuous and binary variables using cohort-specific biomarker positivity thresholds. Association of plasma P-tau217 with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by &lt;i>APOE&lt;/i> genotype. Adjusted survival curves and re</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-12T03:14:53.452Z</modification><creation>2026-07-12T03:11:15.578Z</creation></dates><accession>S-EPMC12919147</accession><cross_references><pubmed>41728301</pubmed><doi>10.64898/2026.02.06.26345774</doi></cross_references></HashMap>